TY - JOUR T1 - Evaluation of contribution of high frequency chest wall oscillation treatment to medical treatment in patients with acute exacerbations of COPD JF - European Respiratory Journal JO - Eur Respir J VL - 38 IS - Suppl 55 SP - p1245 AU - Tugba Goktalay AU - Selim Akdemir AU - Aysin Coskun AU - Aylin Alpaydin AU - Pinar Celik AU - Arzu Yorgancioglu Y1 - 2011/09/01 UR - http://erj.ersjournals.com/content/38/Suppl_55/p1245.abstract N2 - Vest TM device which applies high frequency chest wall oscillation has been approved by FDA for the clearance of bronchial secretions in 1988 and for the induction of sputum in 2000. It has been used in abroad but not in Turkey yet. In this study, we aimed to investigate the contribution of VestTM device to the conventional treatment in COPD exacerbations.Thirty stage 3-4 (GOLD) COPD patients with acute exacerbation were included in the study. Patients were randomized as group I; standard treatment and group II; standard treatment + Vest TM (20 minutes,3 times a day for 5 days). Basal, third and fifth day BODE index, arterial blood gas of the patients were evaluated.VestTM device was applied to 16 of 30 patients.Basal BODE index of the study groups was not statistically different, also mean age was similar. BODE index, PO2 and SO2 of the patients were statistically better both on the third and fifth days (Table). There was a 4% increase from basal FEV1 of GroupI, while this difference was 6% in GroupII (p=0.002,p=0.002), similarly the increase in 6MWT was 107m in Group I while it was 150m in VestTM group (p=0.000, p=0.000). Although MMRC dyspnea scale did not statistically different, the VestTM group reported decreased dyspnea perception (p=0.055). BODE index (p=0.801, p=0.595) and SpO2 (p=0.640, p=0.870) were not found different between the two groups.Adding Vest TM to conventional treatment in COPD exacerbations did not result in any difference in BODE index, however exercise capacity and dyspnea perception were found to be improved more with Vest TM. ER -